Nagel Photography / Shutterstock.com
Biopharma parties thinking about challenging a patent via an inter partes review should be aware that there are significant differences between district court and IPR practice, as Tasha Francis and Dorothy Whelan of Fish & Richardson explain.
The America Invents Act introduced several new procedures for challenging patent validity at the US Patent and Trademark Office (USPTO). One of those procedures is the inter partes review (IPR), which became available on September 16, 2012. The IPR is a procedure for challenging patentability based on patents and printed publications.
Anyone other than the patent owner can file an IPR petition. The IPR is conducted before a tribunal of administrative judges who are members of the Patent Trial and Appeal Board (PTAB). The IPR process is called a trial, although it differs significantly from a trial in a civil action in terms of judicial standards, procedures and presumptions. IPRs are attractive to parties seeking to challenge the validity of patents because they offer reduced cost and time.
Since September 2012, more than 3,100 IPR petitions have been filed. While the majority of IPRs filed cover the mechanical and electrical arts, the number of IPRs filed related to the biopharmaceutical space has steadily increased from nine in 2012 to 84 filed to date this year. As a result, biopharma IPRs account for an estimated 7.7% of all IPRs (based on USPTO statistics).
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Tasha Francis; Dorothy Whelan; Fish & Richardson; USPTO; IPR; PTAB; NPEs, patent; district court